BioX­cel says in­de­pen­dent au­dit of Alzheimer’s study found mis­con­duct did not im­pact da­ta re­li­a­bil­i­ty

BioX­cel Ther­a­peu­tics said Wednes­day that it still plans to use da­ta from a site in its Phase III Alzheimer’s dis­ease study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.